ArticleKidney international2015
New lessons from randomized trials in steroid-sensitive nephrotic syndrome: clear evidence against long steroid therapy.
Article in Kidney international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse.Italian journal of pediatrics · 2017Pooled it
- Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial.Pediatric nephrology (Berlin, Germany) · 2016Trial
- Childhood idiopathic nephrotic syndrome: recent advancements shaping future guidelines.Pediatric nephrology (Berlin, Germany) · 2025Review
- Mycophenolate Mofetil Versus Prednisone for Induction Therapy in Steroid-Sensitive Idiopathic Nephrotic Syndrome in Children: An Observational Study.Kidney medicine · 2024Article
- Treatment of idiopathic nephrotic syndrome at onset: a comparison between 8- and 12-week regimens in everyday clinical practice.Pediatric nephrology (Berlin, Germany) · 2023Article
- Oral cyclophosphamide therapy in 100 children with steroid-sensitive nephrotic syndrome: experience from a developing country.Pediatric nephrology (Berlin, Germany) · 2021Observational
- Childhood Idiopathic Nephrotic Syndrome: Does the Initial Steroid Treatment Modify the Outcome? A Multicentre, Prospective Cohort Study.Frontiers in pediatrics · 2021Article
- Five-year outcome of children with idiopathic nephrotic syndrome: the NEPHROVIR population-based cohort study.Pediatric nephrology (Berlin, Germany) · 2019Article
- Initial treatment of steroid-sensitive idiopathic nephrotic syndrome in children with mycophenolate mofetilBMJ open · 2018Article
- Article
- Nephrotic syndrome: what's new, what's hot?Korean journal of pediatrics · 2015Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The best initial therapy for steroid-sensitive nephrotic syndrome (SSNS) in children is subject to ongoing debate. Systematic reviews and meta-analyses have concluded that at least 3 months and up to 7 months of treatment would reduce the number of relapses by 30%. But summarizing small underpowered studies cannot eliminate the basic flaws in design. Two well-powered randomized prospective trials now come to the opposite conclusion, and these results should impact the management of children with SSNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.